Poster Session : PS 1502 ; Rheumatology : Cross-Cultural Validation of Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient index Data (RAPID) in Korean Rheumatoid Arthritis Patients

Background: No single “gold standard” to evaluate disease activity is available for rheumatoid arthritis (RA). The most used indices are DAS28, SDAI, CDAI and routine assessment of patient index data (RAPID)3. The objective of this study is to evaluate these four indices in a cohort of patient with RA from Korea and to assess the correlation with RAPID3, the internal consistency and the test-retest reliability of the measures to calculate the RAPID3. Methods: Multi-dimensional health assessment questionnaire (MDHAQ) and RAPID3 original version was translated and back-translated by two Korean rheumatologists. A cohort of 57 patients with RA, who were diagnosed by 2010 revised ACR/EULAR criteria, were evaluated. Data were collected at baseline tender joint count (TJC), swollen joint count (SJC), C reactive protein (CRP), patient global estimate (PATGL) and physician global (DOCGL). The test-retest reliability of three indices were calculated at baseline and after one week period. The correlation of three indices with DAS28, SDAI, CDAI was investigated. Statistical evaluation was carried out by calculating the Cronbach alpha, the Spearman rank correlation and the intraclass correlation (ICC) using Stata ver 13.0. Results: Internal consistency was the highest for RAPID3 (alpha=0.87) and the lowest for the DAS28 (0.25). The variable with higher ICC was pain (0.93, 95% con. dence interval 0.89~0.96), follow by PATGL (0.83, 95% con. dence interval 0.74~0.90) and function (0.71, 95% con. dence interval 0.57~0.82). The ICC for RAPID3 including the three variables was 0.91, 95% con. dence interval 0.86~0.95. DAS28, SDAI, CDAI and RAPID3 were signi. cantly correlated to one another with the highest correlation between RAPID3 and CDAI (Spearman`s rho=0.74, p<0.01). Conclusions: Korean version of MDHAQ and RAPID3 shows adequate reliability and validity in assessing disease activity in rheumatoid arthritis.